BRPI1014224A2 - composto, composição farmacêutica,e, método para tratar um estado. - Google Patents

composto, composição farmacêutica,e, método para tratar um estado.

Info

Publication number
BRPI1014224A2
BRPI1014224A2 BRPI1014224A BRPI1014224A BRPI1014224A2 BR PI1014224 A2 BRPI1014224 A2 BR PI1014224A2 BR PI1014224 A BRPI1014224 A BR PI1014224A BR PI1014224 A BRPI1014224 A BR PI1014224A BR PI1014224 A2 BRPI1014224 A2 BR PI1014224A2
Authority
BR
Brazil
Prior art keywords
treating
compound
condition
pharmaceutical composition
pharmaceutical
Prior art date
Application number
BRPI1014224A
Other languages
English (en)
Inventor
R Beauglehole Anthony
w schmidtmann Frank
M Rieger Jayson
D Thompson Robert
Original Assignee
Forest Laboratories Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Laboratories Holdings Ltd filed Critical Forest Laboratories Holdings Ltd
Publication of BRPI1014224A2 publication Critical patent/BRPI1014224A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BRPI1014224A 2009-06-30 2010-06-30 composto, composição farmacêutica,e, método para tratar um estado. BRPI1014224A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22169209P 2009-06-30 2009-06-30
PCT/US2010/040651 WO2011002917A1 (en) 2009-06-30 2010-06-30 Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as a2a r agonists

Publications (1)

Publication Number Publication Date
BRPI1014224A2 true BRPI1014224A2 (pt) 2019-09-24

Family

ID=42562595

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014224A BRPI1014224A2 (pt) 2009-06-30 2010-06-30 composto, composição farmacêutica,e, método para tratar um estado.

Country Status (13)

Country Link
US (1) US8263762B2 (pt)
EP (1) EP2448953A1 (pt)
JP (1) JP2012532140A (pt)
KR (1) KR20120107065A (pt)
CN (1) CN102666563A (pt)
AU (1) AU2010266313A1 (pt)
BR (1) BRPI1014224A2 (pt)
CA (1) CA2766073A1 (pt)
CL (1) CL2011003355A1 (pt)
EA (1) EA201270102A1 (pt)
IL (1) IL217190A0 (pt)
MX (1) MX2012000113A (pt)
WO (1) WO2011002917A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
MX367879B (es) 2012-08-01 2019-09-10 Lewis And Clark Pharmaceuticals Inc N-alquil 2-(disustituido)alquiladenosin-5-uronamidas como agonistas a2a.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
UA72912C2 (uk) 1999-02-01 2005-05-16 Юніверсіті Оф Вірджінія Патент Фаундейшн Композиція для лікування запальної реакції
US20010051612A1 (en) 2000-02-23 2001-12-13 Gloria Cristalli 2-Thioether A2A receptor agonists
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
ES2279903T3 (es) 2001-12-18 2007-09-01 Cv Therapeutics, Inc. Antagonistas del receptor a2a de adenosina.
CA2474337A1 (en) 2002-01-25 2003-07-31 Muscagen Limited Compounds useful as a3 adenosine receptor agonists
US6914053B2 (en) * 2002-09-09 2005-07-05 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
WO2004037804A1 (en) 2002-10-22 2004-05-06 Oscotec Inc. Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
NZ541651A (en) 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
CA2565037A1 (en) 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
WO2005117910A2 (en) 2004-05-26 2005-12-15 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
AU2005267706B2 (en) * 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
WO2006101920A2 (en) 2005-03-18 2006-09-28 University Of Rochester Compositions and methods related to the manipulation of adenosine 2a receptor signaling for the treatment of hiv associated neuronal damage
US7589076B2 (en) 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US7985754B2 (en) * 2006-07-17 2011-07-26 Trovis Pharmaceuticals, Llc Selective antagonists of A2A adenosine receptors

Also Published As

Publication number Publication date
WO2011002917A1 (en) 2011-01-06
MX2012000113A (es) 2012-02-29
CL2011003355A1 (es) 2012-10-19
JP2012532140A (ja) 2012-12-13
US20110003766A1 (en) 2011-01-06
EP2448953A1 (en) 2012-05-09
EA201270102A1 (ru) 2012-08-30
CN102666563A (zh) 2012-09-12
US8263762B2 (en) 2012-09-11
CA2766073A1 (en) 2011-01-06
KR20120107065A (ko) 2012-09-28
IL217190A0 (en) 2012-02-29
AU2010266313A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
BRPI0909691A8 (pt) composto, método para preparar um composto, e, composição farmacêutica
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BR112015001098A2 (pt) composto, composição farmacêutica e método para o tratamento de uma condição de doença.
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI1012792A2 (pt) composto, método para controlar plantas, e, composição herbicida
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI1012892A2 (pt) composto, e, composição farmacêutica.
BRPI0915382A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI0908092A2 (pt) Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BRPI1011592A2 (pt) "composição, e, método para fazer manutenção em um furo de poço."
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
BR112012000623A2 (pt) composição de emulsão estabilizada, método, e, método para preparar uma composição de emulsão estabilizada
BR112012001361A2 (pt) composição de aço para mancal, componente de mancal, mancal, e, método para formar um componente de mancal.
BRPI1016132A2 (pt) composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável.
BRPI1014547A2 (pt) composto, e, processo para preparar um composto.
BRPI1011888A2 (pt) processo para preparar um composto, e, composição.
BRPI1013878A2 (pt) método para tratar distúrbios metabólicos, e, composto
BRPI0909198A2 (pt) composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI1011620A2 (pt) composição, composto, e, método de diluição.
BRPI1014691A2 (pt) Composto, e, processo para a preparação de um composto.
BRPI1011531A2 (pt) composto, e , método para fluoração de 18f.
BRPI0917345A2 (pt) composição, e, método para produzir uma composição estabilizada.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.